<DOC>
	<DOC>NCT01609205</DOC>
	<brief_summary>The purpose is to study the relationship between RA disease activity based on Doppler quantification and the subsequent clinical response (EULAR response) to treatment with Adalimumab during 12 months. The purpose is also to compare the Doppler quantification with conventional clinical methods and semiquantitative Doppler assessment.</brief_summary>
	<brief_title>Doppler Evaluation in RA Patients After Adalimumab.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult patient (&gt; 18 years of age), male or female Rheumatoid arthritis according to the 1987 ACR or 2010 EULAR/ACR classification criteria Moderate to high disease activity Ongoing antirheumatic treatment with DMARD, with stable dosage during the last 3 months, and being a candidate for antiTNF addon therapy OR ongoing treatment with first antiTNF therapy and being a candidate for switch to another antiTNF therapy Women with childbearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study Signed Informed Consent *Signed Informed Consent must be obtained before any study specific procedures take place. Biologic treatment with Adalimumab before inclusion Two or more ongoing biologic treatments before inclusion Treatment with other biologic treatment than antiTNF therapy before inclusion Any contraindication for treatment with Adalimumab Intraarticular corticosteroid injection during the last 4 weeks before each followup visit Positive for tuberculosis or hepatitis B. Ongoing pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>